Invitrogen Corporation (NASDAQ: IVGN) is a global company with revenues of $1.2 billion. We provide products and services to pharmaceutical and biotechnology companies, as well as academic and government research institutions.
More than 4,800 employees work for Invitrogen and we conduct business in over 70 countries. We offer more than 25,000 unique products and services to support disease research, drug discovery and commercial bio-production.
The company’s areas of focus include genomics, proteomics, bioinformatics, cell culture, and cell biology, among others. Importantly, we continue to expand our capabilities by partnering with the brightest minds in the world on revolutionary diagnostic methods and therapeutic treatments.
Invitrogen’s product family includes many of the most widely recommended names in the industry, including Molecular Probes, BioReliance, Gibco, and Dynal Biotech. Our products can be found in nearly every major laboratory in the world. Many of the greatest medical discoveries of the last two decades were made using Invitrogen products, including the discovery of the AIDS virus, advancements in cancer treatment, and the development of tools to assist in stem cell research.